Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Infect Dis
Hlavní autoři: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Konopleva, Marina, Kadia, Tapan M, Borthakur, Gautam, Ravandi, Farhad, Masarova, Lucia, Takahashi, Koichi, Estrov, Zeev, Yilmaz, Musa, Daver, Naval, Pemmaraju, Naveen, Naqvi, Kiran, Rausch, Caitlin R, Marx, Kayleigh R, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Major Articles and Commentaries
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130026/
https://ncbi.nlm.nih.gov/pubmed/32236406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa358
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky